Evaxion Biotech A/S Stock Price, News & Analysis (NASDAQ:EVAX) $0.61 -0.21 (-25.60%) (As of 03:46 PM ET) Add Compare Share Share Today's Range$0.55▼$0.7750-Day Range$0.68▼$1.1752-Week Range$0.47▼$2.44Volume751,997 shsAverage Volume275,072 shsMarket Capitalization$17.03 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Evaxion Biotech A/S MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,172.7% Upside$7.00 Price TargetShort InterestHealthy0.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector299th out of 949 stocksBiological Products, Except Diagnostic Industry48th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Evaxion Biotech A/S has a forecasted upside of 1,172.7% from its current price of $0.55.Amount of Analyst CoverageEvaxion Biotech A/S has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.78% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 22.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVAX. Previous Next 3.4 News and Social Media Coverage News SentimentEvaxion Biotech A/S has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evaxion Biotech A/S this week, compared to 1 article on an average week.Search Interest2 people have searched for EVAX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.58% of the stock of Evaxion Biotech A/S is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvaxion Biotech A/S has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Evaxion Biotech A/S Stock (NASDAQ:EVAX)Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.Read More EVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVAX Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comShort Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 22.8%November 28, 2023 | finance.yahoo.comEvaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | finance.yahoo.comEvaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer ImmunotherapyNovember 9, 2023 | morningstar.comADRs End Lower; Evaxion Biotech A/S Declines 30%November 6, 2023 | finance.yahoo.comEvaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan KhattakOctober 31, 2023 | morningstar.comADRs Hold Steady; Fresh2 Group Climbs 23%October 31, 2023 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01December 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | finance.yahoo.comEvaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01October 26, 2023 | finanznachrichten.deEvaxion Biotech: New and Exciting Clinical Data on Evaxion's AI-Immunology-Based Personalized Cancer Vaccines to be PresentedOctober 26, 2023 | tmcnet.comNew and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be PresentedOctober 26, 2023 | finance.yahoo.comNew and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be PresentedOctober 5, 2023 | finance.yahoo.comEvaxion Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySeptember 21, 2023 | finance.yahoo.comEvaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea JabSeptember 20, 2023 | finanznachrichten.deEvaxion Biotech: Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against GonorrheaSeptember 20, 2023 | finance.yahoo.comEvaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against GonorrheaSeptember 18, 2023 | finance.yahoo.comEvaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical companyAugust 30, 2023 | bloomberg.comNovo Buys Embark Biotech to Find New Avenues for Weight LossAugust 29, 2023 | finanznachrichten.deEvaxion Biotech: Evaxion announces Executive Management Changes to strengthen the AI-strategyAugust 29, 2023 | finance.yahoo.comEvaxion announces Executive Management Changes to strengthen the AI-strategyAugust 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rising, Backed by Mostly Firmer MarketsAugust 23, 2023 | finance.yahoo.comEvaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call TranscriptAugust 23, 2023 | finance.yahoo.comQ2 2023 Evaxion Biotech A/S Earnings CallAugust 18, 2023 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Business Update and Second Quarter 2023 Financial ResultsAugust 18, 2023 | finance.yahoo.comEvaxion Announces Business Update and Second Quarter 2023 Financial ResultsAugust 3, 2023 | msn.comEvaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 CatalystSee More Headlines Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/22/2023Today12/05/2023Next Earnings (Estimated)12/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVAX CUSIPN/A CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees63Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+902.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-452.78% Return on Assets-126.54% Debt Debt-to-Equity Ratio3.95 Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book2.00Miscellaneous Outstanding Shares27,919,000Free Float16,294,000Market Cap$19.50 million OptionableNot Optionable Beta0.08 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Niels Iversen Moller M.D. (Age 44)Co-Founder, VP of Business & Director Comp: $120kMr. Andreas Holm Mattsson (Age 47)Co-Founder and Chief AI & Culture Officer Comp: $319kMr. Jesper Nyegaard Nissen (Age 53)CFO & COO Comp: $346.97kDr. Birgitte Rono Ph.D. (Age 47)Chief Scientific Officer Comp: $336kMr. Christian Kanstrup (Age 51)Chief Executive Officer Dr. Jürgen Langhärig EMBAPh.D., Head of Business Development & Member of Advisory BoardMore ExecutivesKey CompetitorsSorrento TherapeuticsNASDAQ:SRNEAIM ImmunoTechNYSE:AIMElevation OncologyNASDAQ:ELEVEntera BioNASDAQ:ENTXPluriNASDAQ:PLURView All CompetitorsInstitutional OwnershipAE Wealth Management LLCBought 48,633 shares on 10/11/2023Ownership: 0.176%View All Institutional Transactions EVAX Stock Analysis - Frequently Asked Questions Should I buy or sell Evaxion Biotech A/S stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVAX shares. View EVAX analyst ratings or view top-rated stocks. What is Evaxion Biotech A/S's stock price target for 2024? 1 Wall Street research analysts have issued 1-year price targets for Evaxion Biotech A/S's shares. Their EVAX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,172.7% from the stock's current price. View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts. How have EVAX shares performed in 2023? Evaxion Biotech A/S's stock was trading at $1.7750 on January 1st, 2023. Since then, EVAX shares have decreased by 69.0% and is now trading at $0.55. View the best growth stocks for 2023 here. Are investors shorting Evaxion Biotech A/S? Evaxion Biotech A/S saw a decrease in short interest in November. As of November 15th, there was short interest totaling 217,400 shares, a decrease of 22.8% from the October 31st total of 281,600 shares. Based on an average trading volume of 140,900 shares, the days-to-cover ratio is presently 1.5 days. View Evaxion Biotech A/S's Short Interest. When is Evaxion Biotech A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 11th 2023. View our EVAX earnings forecast. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. When did Evaxion Biotech A/S IPO? (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. Who are Evaxion Biotech A/S's major shareholders? Evaxion Biotech A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include AE Wealth Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Evaxion Biotech A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EVAX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.